In vivo virulence of Candida albicans isolates causing mucosal infections in people infected with the human immunodeficiency virus

Keyphrases

• AIDS/HIV 100%
• Fluconazole 100%
• Virulence 100%
• Candida Albicans (C. albicans) 100%
• Mucosal Infection 100%
• In Vivo Virulence 100%
• Refractory Infection 66%
• Murine Model 33%
• Prolonged Survival 33%
• Host Factors 33%
• Mortality Rate 33%
• Growth Rate 33%
• Infection Site 33%
• Human Immunodeficiency Virus Infection 33%
• Virus Diseases 33%
• C.albicans 33%
• In Vitro Growth 33%
• Reduced Mortality 33%
• Host Defense Mechanisms 33%
• Clinical Failure 33%
• Mucosal Candidiasis 33%
• Chronic mucocutaneous Candidiasis 33%
• Vulvovaginal Candidiasis 33%
• Infected People 33%
• Antifungal Susceptibility 33%
• Fungal Burden 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• HIV 100%
• Candida Albicans 100%
• Fluconazole 60%
• Mortality Rate 20%
• Virus Infection 20%
• Human Immunodeficiency Virus Infection 20%
• Host Factor 20%
• Invasive Candidiasis 20%
• Vagina Candidiasis 20%
• Mucocutaneous Candidiasis 20%

Immunology and Microbiology

• Human Immunodeficiency Virus 100%
• Candida Albicans 100%
• Host Resistance 33%
• Human Immunodeficiency Virus Infection 33%
• Host Factor 33%
• Mortality Rate 33%
• Antifungal Susceptibility 33%